Cancer vaccine win restores Wall Street’s faith in Moderna

Moderna and Merck announced positive Phase 3 trial results for intismeran, an individualized cancer vaccine designed to work alongside the immunotherapy Keytruda in melanoma patients following surgery. The announcement triggered substantial market enthusiasm, with Moderna shares rising more than 170% in a single day, adding nearly $45 billion to the company’s market capitalization. Partner Merck’s shares and those of rival BioNTech, which develops similar vaccine technology, also ex